Single versus combination antibiotic therapy in adults hospitalised with community acquired pneumonia.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 23076390.
- Also identified by DOI 10.1136/thoraxjnl-2012-202296.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The benefits of β-lactam/macrolide combination therapy over β-lactam therapy alone for the treatment of hospitalised community-acquired pneumonia (CAP) in relation to pneumonia severity are uncertain. We studied 5240 adults hospitalised with CAP from 72 secondary care trusts across England and Wales. The overall 30-day inpatient (IP) death rate was 24.4%. Combination therapy was prescribed in 3239 (61.8%) patients. In a multivariable model, combination therapy was significantly associated with lower 30-day IP death rate in patients with moderate-severity CAP (adjusted OR 0.54, 95% CI 0.41 to 0.72) and high-severity CAP (adjusted OR 0.76, 95% CI 0.60 to 0.96) but not low-severity CAP.
Medical subject headings
- Anti-Bacterial Agents
- Community-Acquired Infections
- Inpatients
- Pneumonia